US Patent

US8420596 — Macrocyclic hepatitis C serine protease inhibitors

Composition of Matter · Assigned to Abbott Laboratories · Expires 2031-04-10 · 5y remaining

Vulnerability score 10/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects novel macrocyclic compounds used to treat a hepatitis C infection in a subject.

USPTO Abstract

The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.

Drugs covered by this patent

Patent Metadata

Patent number
US8420596
Jurisdiction
US
Classification
Composition of Matter
Expires
2031-04-10
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Abbott Laboratories
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.